文献速递中毒与环境急症儿科与产科急症

美国毒物中心报告的年幼儿童阿塞那平、伊潘立酮与鲁拉西酮暴露情况

Asenapine, iloperidone and lurasidone exposures in young children reported to U.S. poison centers.
PubMed 文献 · Clin Toxicol (Phila) · 2017-10-10
一句话结论6岁以下儿童单药暴露于三种新型非典型抗精神病药中,鲁拉西酮最轻、伊潘立酮最重,有症状者急诊观察8小时足以做出分诊决策。

该研究回顾性分析美国国家毒物数据系统2010至2015年6岁以下儿童单药暴露于阿塞那平、伊潘立酮或鲁拉西酮且随访至已知结局的病例,共纳入阿塞那平95例、伊潘立酮64例、鲁拉西酮124例。96%的病例为探索性摄入。嗜睡/昏睡在伊潘立酮中最常见(45%)、鲁拉西酮中最少(8%),伊潘立酮有2例出现呼吸抑制。鲁拉西酮的编码结局以无效应为主(81%),伊潘立酮的中度效应(19%)和重症监护入院(22%)比例最高。作者认为,有症状儿童在急诊观察8小时足以根据临床效应的持续或缓解做出分诊决策。

要点

  • 6岁以下儿童单药暴露中,鲁拉西酮最轻(无效应81%)、伊潘立酮最重(中度效应19%、重症监护入院22%)。
  • 伊潘立酮暴露者嗜睡/昏睡发生率45%,高于阿塞那平与鲁拉西酮,并有2例出现呼吸抑制。
  • 鲁拉西酮暴露者嗜睡/昏睡仅8%,重症监护入院2%,无中度以上效应报告。
  • 非医疗机构观察病例中80%临床效应持续8小时或更短,急诊治疗/离院病例中72%在8小时或更短。
  • 作者认为,有症状儿童在急诊观察8小时足以根据临床效应持续或缓解做出分诊决策。

适用人群与场景

  • 美国国家毒物数据系统2010至2015年报告的6岁以下儿童单药暴露于阿塞那平、伊潘立酮或鲁拉西酮且随访至已知结局的病例。
  • 96%的病例为探索性摄入。

处置流程与药物剂量

  • 作者认为,有症状儿童在急诊观察8小时足以根据临床效应持续或缓解做出分诊决策。

红旗征与不能漏的情况

  • 伊潘立酮暴露者有2例出现呼吸抑制。

研究设计与关键结果

  • 回顾性研究,美国国家毒物数据系统2010至2015年数据,纳入阿塞那平95例、伊潘立酮64例、鲁拉西酮124例6岁以下儿童单药暴露病例。
  • 嗜睡/昏睡发生率:伊潘立酮45%最高,鲁拉西酮8%最低。
  • 管理地点:非医疗机构现场观察分别为阿塞那平32%、伊潘立酮16%、鲁拉西酮26%;急诊治疗/离院分别为46%、47%、63%;非重症监护入院分别为9%、14%、10%;重症监护入院分别为10%、22%、2%。
  • 临床效应持续时间:非医疗机构病例中80%为8小时或更短,急诊治疗/离院病例中72%为8小时或更短。
  • 编码结局:无效应分别为阿塞那平50%、伊潘立酮41%、鲁拉西酮81%;轻微效应分别为43%、39%、17%;中度效应分别为6%、19%、2%;严重效应分别为0、2%、0。

证据类型、等级与局限

  • 证据类型:回顾性研究,基于美国国家毒物数据系统。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,6岁以下儿童暴露于阿塞那平、伊潘立酮或鲁拉西酮后,有症状者在急诊观察8小时足以根据临床效应持续或缓解做出分诊决策。
  • 作者认为,鲁拉西酮暴露在6岁以下儿童中最不严重,伊潘立酮暴露最严重。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

CONTEXT: Asenapine, iloperidone and lurasidone are relatively new atypical antipsychotics. There is limited information on toxicity on pediatric exposures to these drugs. The objective of this study was to compare toxicity associated with asenapine, iloperidone and lurasidone exposures in young children.

METHODS: A retrospective study of U.S. National Poison Data System from 2010 to 2015 of single substance exposures to asenapine, iloperidone or lurasidone in children <6 years of age that were followed to known outcome was performed.

RESULTS: There were 95 asenapine, 64 iloperidone and 124 lurasidone cases that met inclusion criteria. Reason was exploratory for 96% of cases. Drowsiness/lethargy occurred most frequently with iloperidone (45%) and least often with lurasidone (8%). Two iloperidone cases had respiratory depression. For asenapine, iloperidone and lurasidone, respectively, management sites were on-site non-health care facility (non-HCF) (32%, 16%, 26%), treated/discharged from emergency department (ED) (46%, 47%, 63%), admitted to noncritical care (9%, 14%, 10%) and admitted to critical care (10%, 22%, 2%). Clinical effect duration was 8 h or less for the majority of non-HCF cases (80%) and for children treated/discharged from the ED (72%). For asenapine, iloperidone and lurasidone, coded outcomes were no effect (50%, 41%, 81%), minor effect (43%, 39%, 17%), moderate (6%, 19%, 2%) and major (0, 2%, 0).

DISCUSSION AND CONCLUSIONS: These findings suggest that in children under 6 years of age, lurasidone exposures were least serious and iloperidone exposures were most serious based on clinical effects, management sites and coded outcomes. Observation of symptomatic children in the ED for 8 h should be sufficient to make triage decisions based on persistence or resolution of clinical effects.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Stassinos G, Klein-Schwartz W. Asenapine, iloperidone and lurasidone exposures in young children reported to U.S. poison centers. Clin Toxicol (Phila). 2017. PMID: 28992737. doi:10.1080/15563650.2017.1388385

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。